# Clinical Trials Data KRAS - Document 49

# The Immunoscore as a Prognostic Marker for Patients With a Colorectal Cancer

## Clinical Trial: https://clinicaltrials.gov/study/NCT01688232

"eligibilityCriteria": "Inclusion Criteria:\n\n\* Adult patient with newly diagnosed colorectal cancer.\n\* Patient with signed informed consent.\n\* Follow up made by the clinical center for inclusion or by a medical team in relation with the center.\n\nExclusion Criteria:",  
 "healthyVolunteers": false,  
 "sex": "ALL",  
 "minimumAge": "18 Years",  
"stdAges": [  
"ADULT",  
"OLDER\_ADULT"  
],  
 "studyPopulation": "Adult patient with newly diagnosed colorectal cancer.",

Question:  
Based on the following clinical trial information, would a patient with a KRAS gene mutation be eligible for the clinical trial?

Answer:  
To determine if a patient with a KRAS gene mutation would be eligible for this clinical trial, we need to look for any mention of genetic criteria within the inclusion or exclusion criteria. In the provided information:  
  
\*\*Inclusion Criteria:\*\*  
- Adult patient with newly diagnosed colorectal cancer.  
- Patient with signed informed consent.  
- Follow up made by the clinical center for inclusion or by a medical team in relation with the center.  
  
\*\*Exclusion Criteria:\*\*  
- Not provided in the excerpt.  
  
There is no mention of the KRAS gene mutation in the inclusion or exclusion criteria. Based on the provided information alone, a patient with a KRAS mutation could potentially be eligible since the mutation is not listed as an exclusion criterion, and the inclusion focuses on new colorectal cancer diagnosis and informed consent.  
  
However, without the full exclusion criteria, it's important to verify with the complete trial details if there are any other specific exclusion criteria related to KRAS or any genetic factors. It would also be advisable for the patient or their medical team to confirm eligibility with the clinical trial coordinators or referring physicians.